Annovis Bio
ANVS

$8.47

1.28%

Market Cap: $111M

About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Employees: 6

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 31 [Q1] → 31 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

2.59% less ownership

Funds ownership: 11.4% [Q1] → 8.81% (-2.59%) [Q2]

43% less call options, than puts

Call options by funds: $8.64M | Put options by funds: $15.2M

61% less capital invested

Capital invested by funds: $14.4M [Q1] → $5.67M (-$8.7M) [Q2]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$21

148%

upside

Avg. target

$33

292%

upside

High target

$67

691%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

EF Hutton Jason Kolbert 38% 1-year accuracy 11 / 29 met price target	148%upside $21	Buy Maintained	15 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 114 / 261 met price target	254%upside $30	Buy Reiterated	15 Aug 2024
EF Hutton Jason Kolbert 38% 1-year accuracy 11 / 29 met price target	148%upside $21	Buy Initiated	13 Aug 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 114 / 261 met price target	254%upside $30	Buy Reiterated	17 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 114 / 261 met price target	254%upside $30	Buy Maintained	11 Jul 2024

See Analyst Rankings

Financial journalist opinion

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzheimer's disease.

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Zacks Investment Research

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?

Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions.

Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Zacks Investment Research

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

Annovis Announces New Publication in a Peer-Reviewed Journal

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

Annovis Announces New Publication in a Peer-Reviewed Journal

See News Rankings